Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of APG-1387 in Patients With Chronic Hepatitis B

Next Previous
Trial Profile

A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of APG-1387 in Patients With Chronic Hepatitis B

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs APG 1387 (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; First in man
  • Sponsors Ascentage Pharma

    • Most Recent Events

    • 08 Nov 2022 Interim Results assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of APG-1387 in Chinese patients with Chronic Hepatitis B presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases
    • 06 Nov 2022 Results published in the Ascentage Pharma Media Release
    • 06 Nov 2022 According to the Ascentage Pharma media release, results from this study presented at the 73rd American Association for the Study of Liver Diseases Annual Meeting (AASLD 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top